Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Vaccines: 2023 Year in Review

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

Emerging Leaders

Interactive Tools

PBM Leaders

Subscribe

Articles

Here’s what you missed this week on Managed Healthcare Executive.

MHE Week in Review – Taming Healthcare Costs, Gene Therapy Coverage Challenges and More

Type 1 diabetes is a relentless disease, according to David Maahs, M.D., M.A., Ph.D., from Stanford University.

The Challenges of Treating Type 1 Diabetes

The rising popularity of the continuous glucose monitor, which is not the same as an insulin pump, has been a huge advance in type 1 diabetes treatment, according to David Maahs, M.D., M.A., Ph.D., from Stanford University. 

Comparing and Contrasting Continuous Glucose Monitors and Insulin Pumps

David Maahs, M.D., M.A., Ph.D., explains why teamwork is the most important part of the 4T diabetes management program. 

4T Program Improves Diabetes Outcomes Through Advocacy and Technological Solutions

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

ID Week 2024

AMCP Nexus 2024

AHIP

AIDS Conference

ATS 

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Authors

Jeffrey Hulburt is the president and CEO of Beth Israel Deaconess Care Organization, a value-based physician and hospital network and an Accountable Care Organization in Massachusetts. 

Find out what worked for this value-based physician and hospital network and Accountable Care Organization in Massachusetts. 

Five ACO success tips from Beth Israel Deaconess Care Organization CEO

If priced between $143,900 and $273,700 per treatment cycle, tabelecleucel (tab-cel) would be a cost-effective cell therapy to treat a post-transplant complication, according to an 

 from The Institute for Clinical and Economic Review. Tab-cel is currently being reviewed by U.S. regulators to treat adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Lymphoproliferative disease is a rare but life-threatening 

 after organ or stem-cell transplants. Many cases are associated with Epstein-Barr virus, accounting for more than 75% of post-transplant lymphoproliferative disease, according to one estimate. Most people have been exposed to Epstein-Barr, but the immune suppression drugs used after a transplant can reactivate the virus.

There is no treatment available specifically for Epstein-Barr virus related post-transplant lymphoproliferative disease, but Rituxan (rituximab) and chemotherapy are often used to treat the disease.

“EBV+ PTLD is a rare and often fatal cancer associated with solid organ transplant and stem cell transplant,” ICER’s vice president of research Foluso Agboola, MBBS, MPH, said in a 

. “Unfortunately, approximately half of EBV+ PTLD cases are refractory to initial treatment or relapse, resulting in a poor prognosis. The limited evidence on tabelecleucel suggests that it provides important clinical benefits in patients with relapsed refractory EBV+ PTLD, extending survival for patients who otherwise do not usually survive beyond a few weeks to months, with few harms.”

Tab-cel is an allogeneic, T-cell immunotherapy that, if approved, would administered intravenously for three doses per cycle for a minimum of two cycles. It would be available as an off-the- shelf, T-cell therapy.

The biologics license application for tab-cel is being review by U.S. regulators, and an FDA decision is expected by Jan. 15, 2025. Developed by Atara Biotherapeutics, tab-cel will be marketed in the United States by Pierre Fabre Laboratories, according an 

 between the companies in December 2023. Based on this agreement, all tab-cel manufacturing, clinical, and regulatory activities have been transitioned from Atara to Pierre Fabre Laboratories.

Tab-cel is available in Europe with the brand name Ebvallo and marketed by Pierre Fabre.

ICER has given tabelecleucel a rating of A, indicating the T cell therapy has a high certainty of substantial net health benefit. The analysis indicates that treatment with tab-cel extends survival for patients who otherwise do not usually survive beyond a few weeks to months. The data indicate that the therapy appears to induce partial or complete remission in a substantial proportion of patients with relapsed/refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease.

ICER’s health-benefit price benchmark is a price range suggesting the highest U.S. price, net of rebates and discounts, a manufacturer should charge for a treatment, based on the amount of improvement in overall health patients receive from that treatment.

The BLA is supported by data from more than 43 patients treated with tab-cel across multiple life-threatening diseases, including the single-arm ALLELE study that met its primary endpoint. Interim data from this study found that 22 of 43 (51.2%) Epstein-Barr virus related post-transplant lymphoproliferative disease patients achieved an objective response rate. The median duration of response was 23 months, and the median overall survival was 18.4 months.

In ICER’s analysis, tab-cel resulted in high quality of life years (QALY), equal value of life years (evLY) gained, and life years gained over a lifetime horizon. Based on a placeholder price of $287,500 per 35-day treatment cycle, the incremental cost-effectiveness of tabelecleucel was approximately $183,449 per QALY gained and $156,668 per evLY gained.

Because tab-cel is an off-the-shelf product, the ability to treat patients early would be an advantage, ICER notes. Currently available T cell therapies have lengthy manufacturing times, which can delay treatment.

ICER officials, however, cautioned that the cost-effectiveness findings could be an optimistic estimate given the limited clinical evidence available. The actual cost-effectiveness will be dependent on its actual price and the survival benefit of treatment. The analysis notes that few patients have been treated have been followed for five years.

“Additionally, it is not clear how generalizable the data from the ALLELE study are, since the small sample size and short duration of the trial may obscure differences in treatment effect by transplant type,” the reported noted.

Long-term safety data are also needed to assess potential harms. ICER officials noted there were four events of acute graft versus host disease (GvHD) in three patients reported in the U.S. expanded access program that were considered by investigators to be possibly related to tabelecleucel.

ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.


Formulary Watch

Clinical

ICER Gives Cell Therapy for Post-Transplant Complications High Rating

In a session that discussed the pipeline and a new FDA-approved treatment option for patients with nonalcoholic steatohepatitis (NASH), speakers at the annual meeting of the Academy of Managed Care Pharmacy in New Orleans debated how managed care organizations and health plans can think about coverage for these newer therapies.

Both Donna Cryer, J.D., and Stephanie Spence, Pharm.D., CSP, agreed that there is unmet medical need for patients given the progressive nature of NASH, a severe form of fatty liver disease. NASH is a leading cause of liver-related mortality, especially for those with hypertension and type 2 diabetes. NASH affects between 1.5% and 6.5% of U.S. adults.

Some experts are now calling the disease metabolic dysfunction-associated steatohepatitis, or MASH. But as the speakers pointed out, an ICD 10 code has not yet been established for MASH. The transition to a new code could take some time.

Last month, the FDA granted accelerated approval for Rezdiffra (resmetirom), the first drug approved specifically for NASH. It was approved based on a surrogate endpoint. Treatments that have been used for NASH have included lifestyle modification and off-label use of drugs therapies such as semaglutide or tirzepatide, drugs that are approved to treat diabetes and weight loss.

Rezdiffra is an oral therapy approved based on data from the ongoing phase 3 MAESTRO-NASH trial. At 52 weeks, Rezdiffra achieved liver histological improvement endpoints: resolution of NASH and reduction of liver fibrosis, two surrogate endpoints. It has shown promise in improving liver scarring and even resolving NASH in some patients after one year. 

Spence, who is director of specialty pharmacy at CareFirst BlueCross BlueShield, which serves 3.5 million people in Maryland, the District of Columbia and Northern Virginia, said that payers’ prior authorization for Rezdiffra could consider either noninvasive methods or biopsy as way of  diagnosing NASH, as well as requiring treatment for comorbid conditions, lifestyle modifications and abstinence from alcohol.

Additionally, Spence mentioned that prescribing would be appropriate through specialty providers. “Primary care doctors are overwhelmed by the prospect of managing such a large population with this condition.”

She also suggested that because of the cost of Rezdiffra, payers should consider value-based contracts with manufacturers. The drug's maker, Madrigal Pharmaceuticals, announced in March after the FDA approved Rezdiffra that it would price drug to cost $47,400 per year. 

“There are opportunities, especially as we look at the NASH treatment pipeline, to bring some innovation to the contracts that we have with manufacturers, specifically around outcomes,” said Spence, who suggested that there are still questions about where Rezdiffra fits into NASH treatment. “Are we actually preventing the progression of NASH with these therapies? Or are we just tacking on another therapy?" she asked.

During the question and answer part of the session, Donna Cryer, founder and CEO of the patient organization Global Liver Institute, addressed the importance of payers following therapies’ approved labels. For example, she pointed out that Rezdiffra’s label does not require biopsies; instead, patients can be diagnosed with ultrasound imaging or blood tests for biomarkers of liver fibrosis. “I would not want to see a prior authorization require a biopsy since that is not on the label,” Cryer said.

Additionally, Cryer said that the requirement to abstain from alcohol also is not on the label. “The nomenclature of this disease was to create a category separate from alcohol-related liver disease. Certainly, patients should be counseled about the impact of alcohol on the liver. But it’s important to patients to explain to families that this is not about alcohol." 

Spence said it is common to require abstention from alcohol for liver diseases because of its impact on the liver. “It’s also in the study design [of Rezdiffra]. There is room for discussion but it is a standard criteria for drugs that are modifying the liver.”

She also said payers should review requiring patients to step through current treatment options, especially with the GLP-1, before being prescribed Rezdiffra

Cryer, however, suggested that requiring steps could make it harder for patients to access needed therapy. “I see this as an opportunity rather than something required. I think this is an opportunity to optimize people’s metabolic profile."

Even with the approval of Rezdiffra, Cryer and Spence agree that a huge need for additional treatments and equitable access remains. Therapies in development are targeting various aspects of the disease, including inflammation, fibrosis and bile acid regulation. They offer the potential to slow or reverse disease progress.

Semaglutide, currently approved as Ozempic to treat diabetes and as Wegovy for weight loss, is in a phase 3 trial for a NASH indication. It is a GLP-1 agonist, which have been used off label for NASH. Other drugs in phase 3 trials include:

Azemiglitizone, an oral thiazolidinedione

Belapectin, an intraveneous galectin inhibitor

Efruxifermin, a subcutaneous fibroblast growth factor mimetic

The pipeline for NASH treatments is robust, with six therapies in phase 3 development. Speakers at the annual AMCP meeting discuss Rezdiffra, the first drug approved specifically for NASH, and how to think about coverage issues.

Providing Access to Rezdiffra for NASH and the Therapies to Come | AMCP 2024

The best strategy for treatting optics neuritis, the importance of complete elimination of subretinal fluid and many other long-held beliefs in ophthalmology were challenged during a session Saturday focused on breaking down myths at the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago.

The moderator of the session, Sruthi Arepalli, M.D., noted that new research findings can chip away at cherished notions about diagnosis and treatment that were once held firmly as true.

“Things change with time as more data comes,” said Arepalli, an assistant professor in the Department of Ophthalmology at the Emory School of Medicine in Atlanta.

Optic neuritis: To treat (and test) or not to treat (and not to test)

John J. Chen, M.D., Ph.D., a neuro-ophthalmologist at the Mayo Clinic, said the belief that optic neuritis tends to get better on its own stemmed from a landmark study published in the 

 in 1992. Findings from that study established that high-dose intravenous methylprednisolone can speed recovery but, ultimately, it does not change visual acuity.

But Chen told AAO audience that “not all cases of optic neuritis will improve without intervention, and understanding the underlying pathology is essential for effective management.” Testing for specific antibodies is crucial, he said, because it can significantly influence prognosis and guide treatment choices.

Although some cases will optic neuritis resolve, Chen said, but others may get much worse. Neuromyelitis optica, for example, can lead to blindness and needs to be treated, he noted. It is important to uncover the underlying pathology of optic neuritis, Chen continued, and specifically whether it is related to multiple sclerosis or myelin oligodendrocyte glycoprotein, both of which could dramatically alter the approach to treatment.

Testing for AQP4 and MOG antibodies is crucial to differentiating between the types of optic neuritis and making treatment choices, said Chen.

To further illustrate that treatment is often needed, Chen shared a case scenario wherein there was testing and antibody detection followed by intervention and another with no testing. The outcomes were vastly different because the testing identified AQP4-positive neuromyelitis optica spectrum disorder, leading to early intervention with Uplizna (inebilizumab) and avoidance of paralysis. 

Macular degeneration: Can dry be too dry?

Treating the macula till it is “dry” and the excess fluid removed is often seen as the goal of macular degeneration treatment. Yasha S Modi, M.D., a vitreoretinal surgeon at Tisch Hospital in New York and an associate professor at NYU Grossman School of Medicine, said answers to two main questions could poke a hole in that idea: Does all fluid need to be treated? And should a perfectly dry retina always be the goal? 

Modi told the AAO audience that clinical evidence shows that not all fluid is the result of neovascularization. Subretinal fluid alone may occur in specific situations, such as pigment epithelial detachment (PED), and in many cases doesn’t require treatment, he said.

“Not all fluid is necessarily neovascular ... and in rare cases, even with neovascularization, we can observe closely, if asymptotic and with excellent visual acuity," said Modi. The only challenge, he noted, was that these cases were very difficult to identify.

In fact, some research has shown that having a fully dry retina may be less than ideal, Modi said, referencing a post-hoc analysis of the phase 3 

 of ranibizumab. The study participants with some residual subretinal fluid at 12 and 24 months were found to have better best-corrected visual acuity than those with complete resolution of fluid.

Modi emphasized the importance of individualized treatment. Striving for a completely dry retina is not always achievable or necessary, he said, and in some cases persistent subretinal fluid may be protective. “Persistent subretinal fluid may paradoxically be associated with better vision. Perhaps it plays a protective role in preserving photoreceptor health," he said.

Thyroid eye disease: Straightening out the thinking about Rundle’s curve

Rundle's curve is used to define the natural history of thyroid eye disease (TED). Many studies since Francis Felix Rundle’s publication of research in 1945 that became the basis for the eponymous curve have cast doubts on its accuracy, and several anecdotal patient case reports do not align with its timelines, said Amina I. Malik, M.D., chief of ophthalmic plastic and reconstructive surgery at Houston Methodist Hospital.

“I think 80 years later, it’s time to set the record straight on Rundle’s curve,” she said. “Not every patient is going to follow this oversimplified biphasic curve ... it’s time we really focus on their symptoms and quality of life.”

The biggest deviation from the curve is that TED often persists beyond the “inactive” phase, Malik said. This is noted by ongoing inflammation at the cellular level, she said. Although the levels of insulinlike growth factor expression were not as high in those with"noninflammatory" TED, the levels in this group were still much higher than in control arms. This was observed in studies of Tepessa (teprotumumab) for patients with noninflammatory TED.

"There is still persistence of this upregulation and overexpression of growth factor receptors telling us that even if we don't see the external signs of inflammation, there is still some ongoing inflammation happening," said Malik. "It's a complex heterogeneous inflammatory disease."

The good news with uncovering this new complexity is that several therapies are currently in development, she said. Treatment strategies should focus on the patient rather than on Rundle’s curve, Malik said.

Presenters at a myth breakers session at the American Academy of Ophthalmology took aim at some prevailing notions.

Once True. Now, Maybe Not So Much. Toppling Myths in Ophthalmology | AAO 2024

Following the FDA’s Mar. 8 decision to approve semaglutide (Wegovy) as a preventive for stroke and heart disease in overweight individuals, the CMS announced last week that it will soon be covered under their Medicare Part D drug program as well, multiple news outlets 

“This patient population has a higher risk of cardiovascular death, heart attack and stroke," John Sharretts, M.D., director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research said in an FDA 

New development comes after the FDA’s Mar. 8 Wegovy approval for patients at risk for heart attack and stroke.

Jeffrey Hulburt

Articles

Latest Updated Articles